CytoDyn's Leronlimab Shows Positive Responses In COVID-19 Patients

(RTTNews) - CytoDyn Inc. announced a patient with severe COVID-19 in Southern California showed clinical improvement after treatment with the company's investigational new drug, leronlimab. The company noted that this outcome is consistent with that observed in severely ill COVID-19 patients treated with leronlimab at a medical center in New York City.

Additionally, two patients with moderate COVID-19 were treated with leronlimab and showed clinical improvement. An additional four patients with moderate COVID-19 have been administered leronlimab and results are pending, the company noted.

The FDA recently cleared the company to initiate a Phase 2b/3 clinical trial for severe and critically ill COVID-19 patients.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Latest Markets Videos


Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Learn More